Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244855 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00244855 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT00244855, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with dexamethasone may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL rituximab
- DRUG dexamethasone
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-05 |
| Est. Completion | 2011-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244855
The ClinicalTrials.gov registry entry for NCT00244855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00244855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244855 about?
NCT00244855 is a clinical study titled "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma". This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to g...
What is the current status of trial NCT00244855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-05. Estimated completion is 2011-08-29.
What interventions are being tested in trial NCT00244855?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rituximab (BIOLOGICAL), dexamethasone (DRUG), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT00244855?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.